BOULDER, Colo. -- (BUSINESS WIRE) -- Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the U.S. Patent & Trademark Office has granted the company a patent for a new method and system of validating the performance of matrix-assisted, laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometer machines.
Mass spectrometry is central to the proprietary discovery platform that Biodesix developed to evaluate and classify patient samples obtained from its commercially available, blood-based test, VeriStrat. The company’s latest invention, U.S. Patent 8,467,988, fills the need for an objective method that qualifies the performance of Biodesix’ MALDI-TOF mass spectrometer instruments — ensuring that over time, and through the maintenance cycles, the instruments continue to reliably classify biological samples for VeriStrat.
VeriStrat, a clinically validated blood-based protein test, helps physicians guide second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). The test predicts whether patients are likely to benefit from the targeted drug erlotinib, an epidermal growth factor receptor inhibitor (EGFRI), or chemotherapy.
“This key expansion of the Biodesix patent estate is part of our global strategy to protect VeriStrat and our technology platform,” said David Brunel, Chief Executive Officer of Biodesix. “This patent is further proof of our commitment to uphold the highest standards of integrity for our personalized medicine diagnostics and their results.”
For more information about VeriStrat, visit www.veristratsupport.com.
Biodesix is a molecular diagnostics company advancing the development of innovative products for personalizing medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’ first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’ CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information on VeriStrat, please visit www.VeriStratSupport.com. For more information about Biodesix, please visit www.Biodesix.com.
This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.